CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CytomX Therapeutics (Nasdaq: CTMX), a pioneering company in masked, conditionally activated biologics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Sean McCarthy, D.Phil., the company's CEO and chairman, is scheduled to deliver a presentation on Wednesday, January 15, 2025, at 1:30 p.m. PT.
The presentation will be accessible through a live webcast on the Events and Presentations section of CytomX's website. Additionally, the management team will be available for individual meetings with registered conference investors.
CytomX Therapeutics (Nasdaq: CTMX), un'azienda pionieristica nel settore dei biologici attivati condizionatamente e mascherati, ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan. Sean McCarthy, D.Phil., CEO e presidente dell'azienda, è previsto per una presentazione che si terrà mercoledì 15 gennaio 2025, alle 13:30 PT.
La presentazione sarà accessibile tramite un webcast dal vivo nella sezione Eventi e Presentazioni del sito web di CytomX. Inoltre, il team di gestione sarà disponibile per incontri individuali con gli investitori registrati alla conferenza.
CytomX Therapeutics (Nasdaq: CTMX), una empresa pionera en biológicos activados condicionalmente y enmascarados, ha anunciado su participación en la 43ª Conferencia Anual de Salud de J.P. Morgan. Sean McCarthy, D.Phil., el CEO y presidente de la empresa, pronunciará una presentación el miércoles 15 de enero de 2025, a la 1:30 p.m. PT.
La presentación estará disponible a través de una transmisión web en vivo en la sección de Eventos y Presentaciones del sitio web de CytomX. Además, el equipo de gestión estará disponible para reuniones individuales con los inversores registrados para la conferencia.
사이톰엑스 테라퓨틱스 (Nasdaq: CTMX), 조건부 활성화된 생물학 제제의 선구적인 회사가 제43회 JP모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 션 맥카시, D.Phil., 회사의 CEO이자 회장은 2025년 1월 15일 수요일, 오후 1:30 PT에 발표를 할 예정입니다.
발표는 사이톰엑스 웹사이트의 이벤트 및 발표 섹션에서 생중계로 접속할 수 있습니다. 또한, 경영진 팀은 등록된 컨퍼런스 투자자들과 개별 미팅을 가질 수 있습니다.
CytomX Therapeutics (Nasdaq: CTMX), une entreprise pionnière dans le domaine des biologiques masqués et activés de manière conditionnelle, a annoncé sa participation à la 43e Conférence Annuelle JPMorgan sur la Santé. Sean McCarthy, D.Phil., le PDG et président de la société, doit faire une présentation le mercredi 15 janvier 2025, à 13h30 PT.
La présentation sera accessible via un webinaire en direct dans la section Événements et Présentations du site web de CytomX. De plus, l'équipe de direction sera disponible pour des réunions individuelles avec les investisseurs inscrits à la conférence.
CytomX Therapeutics (Nasdaq: CTMX), ein pionierhaftes Unternehmen im Bereich der maskierten, bedingt aktivierten Biologika, hat seine Teilnahme an der 43. Jahreskonferenz für Gesundheitswesen von J.P. Morgan bekannt gegeben. Sean McCarthy, D.Phil., der CEO und Vorsitzende des Unternehmens, wird am Mittwoch, den 15. Januar 2025, um 13:30 Uhr PT eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast im Bereich Veranstaltungen und Präsentationen auf der Website von CytomX zugänglich sein. Darüber hinaus wird das Management-Team für individuelle Meetings mit registrierten Konferenzinvestoren zur Verfügung stehen.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 p.m. PT.
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ
When is CytomX Therapeutics (CTMX) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch CytomX's (CTMX) J.P. Morgan Healthcare Conference presentation?
Will CTMX management be available for one-on-one meetings at the J.P. Morgan Healthcare Conference?
Who will be presenting for CytomX Therapeutics (CTMX) at the 2025 J.P. Morgan Healthcare Conference?
